

WFS1 A559V — Wolframin

Alanine → Valine at position 559. Lumenal loop 4. ClinVar Uncertain significance/Uncertain risk allele, AlphaMissense 0.778, DynaMut2 $\Delta\Delta G$ -1.16 kcal/mol (destabilising).

IDENTITY

Variant	A559V (p.Alanine559Valine)
DNA change	c.1676C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001521787
Amino acid change	Alanine (A) → Valine (V)

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 559	87.12 HIGH CONFIDENCE
Domain	Lumenal loop 4
Position context	C-terminal lumenal domain · position 559 projects into the ER lumen
IDR flag	No — pLDDT well above 50 threshold

Position 559 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na⁺/K⁺ ATPase β 1. The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.778

am_class: **likely pathogenic** —
threshold > 0.564

DYNAMUT2 $\Delta\Delta G$ **-1.16** kcal/mol

Destabilising · Job
178092118237

PLDDT (ALPHAFOLD)

87.12

high confidence

CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE/UNCERTAIN RISK ALLELE
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2023/10/09 00:00
Inheritance	Autosomal recessive Wolfram syndrome 1 phenotype documented.
WFS1 variant landscape	A559V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Wolfram syndrome 1

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G 2-4$ → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable

$|\Delta\Delta G|=1.16 < 2$ kcal/mol (fold intact) + AlphaMissense 0.778 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution ($|\Delta\Delta G|=1.16$ kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.778. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.